Heeyeon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heeyeon Kim has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ji-Hye Park
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
5 shared publications - Jong Hee Lee
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
5 shared publications - Joonho Shim
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications - Se Jin Oh
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications - Dong-Youn Lee
Department of Dermatology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea
3 shared publications - Hyungrye Noh
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38
Long-Term, Real-World Drug Survival of Biologics in Korean Patients With Moderate-to-Severe Psoriasis: A Single-Center Retrospective Cohort Study
Oh S, et al. Ann Dermatol. 2026 ;38:e79. https://doi.org/10.5021/ad.26.126
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38
Open AccessLong-Term, Real-World Drug Survival of Biologics in Korean Patients With Moderate-to-Severe Psoriasis: A Single-Center Retrospective Cohort Study
Oh S, et al. Ann Dermatol. 2026 ;38:e79. https://doi.org/10.5021/ad.26.126
- Open Access
- 1 January 2025
- Published by XMLink in Annals of Dermatology
- Vol. 37 (1) , 39-45
Appropriate Injection Intervals of Dupilumab in Patients With Adult Atopic Dermatitis: A Step Toward Developing Guidelines for Daily Practice
Kim H, et al. Ann Dermatol. 2024 Oct;36:e65. https://doi.org/10.5021/ad.24.084
- 1 January 2025
- Published by XMLink in Annals of Dermatology
- Vol. 37 (1) , 39-45
Open AccessAppropriate Injection Intervals of Dupilumab in Patients With Adult Atopic Dermatitis: A Step Toward Developing Guidelines for Daily Practice
Kim H, et al. Ann Dermatol. 2024 Oct;36:e65. https://doi.org/10.5021/ad.24.084
- 31 January 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , 858-862
Assessment of hair loss and skin changes during treatment in Asian breast cancer patients: A prospective cohort study
With the increasing number of young breast cancer (BC) patients worldwide, concerns about hair loss and skin change persist among BC survivors. This study aimed to evaluate the hair loss and skin changes in Asian BC patients and to compare them according to the treatment regimens. This study enrolled 322 patients scheduled to undergo BC surgery. Hair loss and skin changes were assessed at the following two time points: one day before surgery and 6 months after surgery. Patients who had received systemic anticancer treatment before surgery were assigned to the neoadjuvant treatment group, while patients who were scheduled to receive systemic anticancer treatment were assigned to the adjuvant treatment group. In the adjuvant treatment group, patients with taxane‐based chemotherapy had significantly higher odds of increased hair loss, a higher melanin index, and an increased volume of wrinkles ( p < 0.0001, p = 0.0110, and p = 0.0371, respectively). In the neoadjuvant treatment group, hair loss was reversed in most patients at 6 months after surgery. Clinicians should inform BC patients about the potential for hair loss and skin changes and provide supportive care to mitigate the effects on the patients’ quality of life.
- 31 January 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , 858-862
Assessment of hair loss and skin changes during treatment in Asian breast cancer patients: A prospective cohort study
With the increasing number of young breast cancer (BC) patients worldwide, concerns about hair loss and skin change persist among BC survivors. This study aimed to evaluate the hair loss and skin changes in Asian BC patients and to compare them according to the treatment regimens. This study enrolled 322 patients scheduled to undergo BC surgery. Hair loss and skin changes were assessed at the following two time points: one day before surgery and 6 months after surgery. Patients who had received systemic anticancer treatment before surgery were assigned to the neoadjuvant treatment group, while patients who were scheduled to receive systemic anticancer treatment were assigned to the adjuvant treatment group. In the adjuvant treatment group, patients with taxane‐based chemotherapy had significantly higher odds of increased hair loss, a higher melanin index, and an increased volume of wrinkles ( p < 0.0001, p = 0.0110, and p = 0.0371, respectively). In the neoadjuvant treatment group, hair loss was reversed in most patients at 6 months after surgery. Clinicians should inform BC patients about the potential for hair loss and skin changes and provide supportive care to mitigate the effects on the patients’ quality of life.
- Open Access
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (5) , 275-281
Skin Hydration Measurement: Comparison Between Devices and Clinical Evaluations
Park JH, et al. Ann Dermatol. 2024 Aug;36:e57. https://doi.org/10.5021/ad.23.103
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (5) , 275-281
Open AccessSkin Hydration Measurement: Comparison Between Devices and Clinical Evaluations
Park JH, et al. Ann Dermatol. 2024 Aug;36:e57. https://doi.org/10.5021/ad.23.103
- 28 November 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (2) , 311-314
Pleomorphic dermal sarcoma presenting in a child with Li‐Fraumeni syndrome: A case report and review of the literature
Pleomorphic dermal sarcoma (PDS) is an uncommon malignant soft‐tissue tumor that occurs mostly in elderly patients, with only 5% of cases occurring in children. However, pediatric patients with Li‐Fraumeni syndrome (LFS) can develop several types of cancer, particularly sarcomas. Here, we describe a young LFS patient who presented with early‐onset PDS and review the literature.
- 28 November 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (2) , 311-314
Pleomorphic dermal sarcoma presenting in a child with Li‐Fraumeni syndrome: A case report and review of the literature
Pleomorphic dermal sarcoma (PDS) is an uncommon malignant soft‐tissue tumor that occurs mostly in elderly patients, with only 5% of cases occurring in children. However, pediatric patients with Li‐Fraumeni syndrome (LFS) can develop several types of cancer, particularly sarcomas. Here, we describe a young LFS patient who presented with early‐onset PDS and review the literature.
- Open Access
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
Clinical Benefit and Safety of Microneedle Patches Composed of Magnesium: A Pilot Study in Acne Patients
Magnesium (Mg) is a newly investigated biomaterial that corrodes physiologically in water, resulting in evolved hydrogen with beneficial effects of anti‐inflammation and acceleration of the wound healing process. In addition, Mg itself has antimicrobial activity against Cutibacterium acnes, which play a pathogenic role in developing inflammatory acne. This study aimed to evaluate efficacy and safety of a newly developed magnesium microneedle (Mg MN) patch, with a needle length of 0.25 mm, on acne and widened pores. A total of 19 patients with mild to moderate acne and receiving no topical or oral treatment was enrolled in the study. Mg MN patches were applied to inflammatory acne lesions and widened pores on both cheeks and nose. Researchers evaluated efficacy by counting acne lesions and measuring pore sizes, porphyrin level, and sebum secretion. Any objective or subjective adverse events were recorded during the study. The number of acne lesions and scores improved significantly within seven days (p < 0.01). The porphyrin level tended to decrease over 12 weeks, although pore size and sebum secretion showed unsatisfactory results. No adverse reactions were noted during the study period. Mg MN patches can be useful in treating inflammatory acne lesions, and they are safe to use. For the improvement of widened pores, modification of needle length or a combination of topical agents may be required.
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
Open AccessClinical Benefit and Safety of Microneedle Patches Composed of Magnesium: A Pilot Study in Acne Patients
Magnesium (Mg) is a newly investigated biomaterial that corrodes physiologically in water, resulting in evolved hydrogen with beneficial effects of anti‐inflammation and acceleration of the wound healing process. In addition, Mg itself has antimicrobial activity against Cutibacterium acnes, which play a pathogenic role in developing inflammatory acne. This study aimed to evaluate efficacy and safety of a newly developed magnesium microneedle (Mg MN) patch, with a needle length of 0.25 mm, on acne and widened pores. A total of 19 patients with mild to moderate acne and receiving no topical or oral treatment was enrolled in the study. Mg MN patches were applied to inflammatory acne lesions and widened pores on both cheeks and nose. Researchers evaluated efficacy by counting acne lesions and measuring pore sizes, porphyrin level, and sebum secretion. Any objective or subjective adverse events were recorded during the study. The number of acne lesions and scores improved significantly within seven days (p < 0.01). The porphyrin level tended to decrease over 12 weeks, although pore size and sebum secretion showed unsatisfactory results. No adverse reactions were noted during the study period. Mg MN patches can be useful in treating inflammatory acne lesions, and they are safe to use. For the improvement of widened pores, modification of needle length or a combination of topical agents may be required.